Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(04): 488-492
DOI: 10.4103/ijmpo.ijmpo_79_17
Original Article

Multidisciplinary Treatment of Pediatric Low-Grade Glioma: Experience of Children Cancer Hospital of Egypt; 2007-2012

Mohamed Ahmed Fawzy
Departments of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Departments of Pediatric Oncology, Children Cancer Hospital of Egypt, Cairo, Egypt
,
Ahmed Ibrahim El-Hemaly
Departments of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
Departments of Pediatric Oncology, Children Cancer Hospital of Egypt, Cairo, Egypt
,
Madeeha Awad
Departments of Pediatric Oncology, Children Cancer Hospital of Egypt, Cairo, Egypt
,
Mohamed El-Beltagy
Department of Neuro Surgey, Cairo University, Cairo, Egypt
,
Mohamed Saad Zaghloul
Departments of Radiotherapy, National Cancer Institute, Cairo University, Cairo, Egypt
,
Hala Taha
Departments of Surgical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt
,
Amal Rifaat
Departments of Radiodiagnosis, National Cancer Institute, Cairo University, Cairo, Egypt
,
Amal Mosaab
Departments of Clinical Research, Children Cancer Hospital of Egypt, Cairo, Egypt
› Author Affiliations Financial support and sponsorship This study was supported by Children Cancer Hospital of Egypt.
› Further Information
   Permissions and Reprints

Abstract

Background: Pediatric gliomas comprise a clinically, histologically, and molecularly heterogeneous group of central nervous system tumors. The survival of children with gliomas influenced by histologic subtype, age, and extent of resection. Tumor grade emerged as the most determinant of survival except in the young age groups. The aim of this study was to evaluate the role of multidisciplinary therapeutic approach including surgery and chemotherapy, and their impact on the outcome in pediatric patients with low-grade glioma (LGG). Procedure: Study patients were prospectively enrolled onto the study. All patients were below 18-year-old, diagnosed as LGG between July 2007 and June 2012. Upfront surgical resection was attempted in all tumors other than optic pathway sites. Systemic chemotherapy was given according to CCG-A9952 protocol. Results: Total/near-total resection in 105/227 (46.3%) without adjuvant treatment, while 49/227 patients (21.5%) underwent subtotal tumor resection followed by chemotherapy for big residual (n = 26). Follow-up only was indicated for asymptomatic/small residual (n = 23). The radiological diagnosis was set in 18/227 (7.9%) patients; 13/18 had optic pathway glioma. The 3-year overall survival (OS) was 87.3% versus 65.5% event free survival (EFS) for the whole study patients with a follow-up period of 1–5 years. The OS and EFS for patients who did surgery with no adjuvant treatment (n = 128) were, respectively, 95.2% and 77.3% versus 87.4% and 65.1% for adjuvant chemotherapy group (n = 99); (P = 0.015 and P = 0.016 for OS and EFS, respectively). Conclusion: Pediatric LGGs comprise a wide spectrum of pathological and anatomical entities that carry a high rate of prolonged survival among children and adolescents. Surgical resection is the mainstay of treatment in most of tumors. Combined chemotherapy can be an acceptable alternative when surgery is not safely feasible.

Keywords

Chemotherapy - low-grade glioma - outcome - pediatric


Publication History

Article published online:
17 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Duffau L, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004; 100: 2622-6
    CrossrefPubMedGoogle Scholar
  • 2 Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001. Cancer 2006; 106: 1358-63
    CrossrefPubMedGoogle Scholar
  • 3 Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H. et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53: 524-8
    CrossrefPubMedGoogle Scholar
  • 4 Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P. et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol 2009; 72: 54-64
    CrossrefPubMedGoogle Scholar
  • 5 Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: The impact of prognostic factors and treatment. Neurology 2007; 69: 1366-73
    CrossrefPubMedGoogle Scholar
  • 6 Soffietti R, Rudà R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998; 43: 1066-73
    CrossrefPubMedGoogle Scholar
  • 7 van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG. et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998; 51: 1140-5
    CrossrefPubMedGoogle Scholar
  • 8 van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M. et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525-8
    CrossrefPubMedGoogle Scholar
  • 9 Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM. et al. Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 2003; 14: 1722-6
    CrossrefPubMedGoogle Scholar
  • 10 Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM. et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646-51
    CrossrefPubMedGoogle Scholar
  • 11 Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F. et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 2007; 68: 1831-6
    CrossrefPubMedGoogle Scholar
  • 12 Agrasti A, Meng X. Strengh in numbers:The rising of academic statistics department in U.S 2012. p.177.
  • 13 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol 2009; 24: 1397-408
    CrossrefPubMedGoogle Scholar
  • 14 Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry 2004; 75 (02) Suppl ii31-6
    PubMedGoogle Scholar
  • 15 Listernick R, Charrow J, Tomita T, Goldman S. Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1. J Neurooncol 1999; 45: 185-90
    CrossrefPubMedGoogle Scholar
  • 16 Czyzyk E, Józwiak S, Roszkowski M, Schwartz RA. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 2003; 18: 471-8
    CrossrefPubMedGoogle Scholar
  • 17 Bandopadhayay P, Bergthold G, London WB, Goumnerova LC, Morales La Madrid A, Marcus KJ. et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 2014; 61: 1173-9
    CrossrefPubMedGoogle Scholar
  • 18 Palma L, Celli P, Mariottini A. Long-term follow-up of childhood cerebellar astrocytomas after incomplete resection with particular reference to arrested growth or spontaneous tumour regression. Acta Neurochir (Wien) 2004; 146: 581-8
    CrossrefPubMedGoogle Scholar
  • 19 Saunders DE, Phipps KP, Wade AM, Hayward RD. Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma. J Neurosurg 2005; 102 (02) Suppl 172-8
    CrossrefPubMedGoogle Scholar
  • 20 Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N. et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: A Canadian pediatric brain tumor consortium study. J Clin Oncol 2016; 34: 3537-43
    CrossrefPubMedGoogle Scholar